Welcome to our dedicated page for PhaseBio Pharmaceuticals news (Ticker: PHAS), a resource for investors and traders seeking the latest updates and insights on PhaseBio Pharmaceuticals stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect PhaseBio Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of PhaseBio Pharmaceuticals's position in the market.
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS) has announced an underwritten public offering of 16,000,000 shares at $3.50 each, aiming to raise approximately $56.0 million. The underwriters have a 30-day option for an additional 2,400,000 shares. The offering is set to close around March 22, 2021, pending standard conditions. Cowen, Stifel, and William Blair manage the offering. The sale is pursuant to a shelf registration declared effective by the SEC on January 8, 2020, and detailed documents are available through the SEC.
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS) has initiated an underwritten public offering of its common stock, aiming to bolster funding for its cardiopulmonary disease therapies. The offering includes a 30-day option for underwriters to purchase additional shares and is governed by a shelf registration statement effective since January 8, 2020. Joint book-runners for the offering are Cowen, Stifel, and William Blair. The final terms will be outlined in a prospectus supplement filed with the SEC. There is no guarantee regarding the offering's completion or specifics.
PhaseBio Pharmaceuticals (Nasdaq: PHAS) released its financial results for Q4 and full-year 2020, highlighting major advancements in its therapeutic pipeline. The company is progressing with the Phase 3 REVERSE-IT trial for bentracimab, now enrolling over 60 patients towards a BLA submission. A commercial supply agreement with BioVectra supports further development. Looking ahead, PhaseBio aims to report Phase 2a data and an interim analysis in 2021, while also developing pemziviptadil for pulmonary arterial hypertension.
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS) has entered a commercial supply agreement with BioVectra Inc. for the production of bentracimab, its lead product candidate. This agreement allows for the manufacturing of the active pharmaceutical ingredient (API) for ongoing clinical trials and future global commercialization. BioVectra successfully completed its first GMP run, and PhaseBio plans to integrate this API into the Phase 2b and Phase 3 REVERSE-IT trials. Bentracimab aims to reverse the antiplatelet effects of ticagrelor, providing potential benefits in urgent medical situations.
PhaseBio Pharmaceuticals (Nasdaq: PHAS), a clinical-stage biopharmaceutical company, will participate in two virtual investor conferences. The Cowen 41st Annual Health Care Conference is scheduled for March 4, 2021, where CEO Jonathan P. Mow will join a panel discussion from 1:30 pm – 2:30 pm ET. The H.C. Wainwright Global Life Sciences Conference will take place on March 9, 2021, with Mow presenting a company overview on demand starting at 7:00 am ET. Webcasts will be available on PhaseBio's website for 90 days post-event.
PhaseBio Pharmaceuticals (Nasdaq: PHAS) will host a virtual Investor and Analyst Day on March 15, 2021, from 12:00 p.m. to 2:00 p.m. ET. The event will highlight the bentracimab development program and update on the Phase 3 REVERSE-IT trial's enrollment status. Bentracimab is a novel monoclonal antibody fragment designed to reverse the effects of ticagrelor. Presenters include leading experts from renowned institutions, and a Q&A session will follow. Interested participants can RSVP and access the live video webcast at the company’s website.
PhaseBio Pharmaceuticals (Nasdaq: PHAS) announced the expansion of its Phase 3 REVERSE-IT trial for bentracimab into the European Union, marking a significant milestone in its development. Bentracimab is designed to reverse the antiplatelet effects of Brilinta® (ticagrelor), aiming to improve management for patients facing urgent surgical needs or major bleeding events. The trial targets enrollment of approximately 200 patients worldwide, with the potential to serve over 1.6 million ticagrelor users across the EU and UK. This expansion follows positive results from previous clinical trials and aims to address critical patient care gaps.
PhaseBio Pharmaceuticals (Nasdaq: PHAS) presented data from a Phase 1b/2a pilot study of pemziviptadil (PB1046) for pulmonary arterial hypertension (PAH) at the PVRI World Congress. Results showed favorable safety, with no serious adverse events in three patients. One patient improved six-minute walk test (6MWT) distance by 78 meters after 18 months, while others maintained stability. The ongoing Phase 2b trial aims to evaluate pulmonary vascular resistance and 6MWT in 60 patients, with initial data expected in the second half of 2021.
PhaseBio Pharmaceuticals (Nasdaq: PHAS) provided updates on its business and reported third-quarter 2020 results. The company expanded its pivotal Phase 3 REVERSE-IT trial for bentracimab into Canada, addressing a significant unmet need in cardiovascular treatment. Enrollment for the Phase 2b VIP trial of pemziviptadil in pulmonary arterial hypertension has resumed. However, PhaseBio discontinued the VANGARD trial related to COVID-19. Financially, the company reported a net loss of $25.1 million, up from $11.4 million year-over-year, with cash decreasing to $39.4 million.
PhaseBio Pharmaceuticals (NASDAQ: PHAS) will have its CEO, Jonathan P. Mow, participate in a fireside chat during the Stifel 2020 Virtual Healthcare Conference on November 18, 2020, at 11:20 a.m. EST. The event can be accessed via a live webcast on the company’s website under the “Investors” section. A replay will be available for 90 days post-event.
PhaseBio focuses on developing novel therapies for cardiovascular and cardiopulmonary diseases, including PB2452, PB1046, and PB6440, leveraging their elastin-like polypeptide technology.
